click below
click below
Normal Size Small Size show me how
Top 200 #9
Class | Brand | Generic | Indication | Dose Form | Route | Adult Dose | Ped Dose | MOA |
---|---|---|---|---|---|---|---|---|
Biphasic Contraceptive Combo (Estrogen and Progestin) | Kariva; Mircette; Ortho Novum 10/11 | Biphasic Contraceptive Combo | Contraception | Varies | Oral | 1 tab QD, same time each day | Safety & efficacy before menarche have not been established | “see mono” |
Triphasic Contraceptive Combo (Estrogen and Progestin) | Ortho Tri-Cyclen; Ortho Tri-Cyclen Lo; Tri-Sprintec; Trivora | Triphasic Contraceptive Combo | Contraception | Varies | Oral | 1 tab QD, same time each day | Safety & efficacy before menarche have not been established | “see mono” |
Contraceptive; Endocrine-Metabolic Agent; Progestin | Nor-QD; Micronor; Camila | Norethindrone | Contraception | Oral Tablet: 0.35mg | Oral | 1 tab QD, same time each day | Safety & efficacy before menarche have not been established | Prevents ovulation, inhibits sperm penetration by thickening the cervical mucus, reduces midcycle luteinizing hormone & follicle-stimulating hormone peaks, delays the movement of ovum through the fallopian tube and alters the endometrium lining |
Contraceptive Estrogen and Progestin Combo | NuvaRing | Ethinyl Estradiol/ Etonogestrel | Contraception | Vaginal Insert (ER): 0.015mg-0.12mg/24hr | Vaginally | Insert 1 ring and wear continuously for 3 weeks, remove for 1 week and repeat with a new ring | Safety & efficacy before menarche have not been established | Suppresses gonadotropins; inhibits ovulation; changes cervical mucus and the endometrium |
Antineoplastic Agnet; Contraceptive; Progestin; Endocrine-Metabolic Agent | Provera | Medroxyprogesterone | Abnormal uterine bleeding unrelated to menstrual cycle; contraception; endometrial hyperplasia; endometriosis; 2® physiologic amenorrhea | Oral Tablet: 2.5, 5, 10mg; SubQ Susp: 104mg/0.65ml IM Susp: 150mg/ml, 400mg/ml; | IM, Oral, SubQ | Tablets: dosing varies; IM injection: done once every 3 months | N/A | Has androgenic & anabolic effects; transforms proliferative into secretory endometrium in women with adequate endogenous estrogen |
Endocrine-Metabolic Agent; Estrogen; Female Reproductive Agent | Premarin | Estrogens (conjugated) | Abnormal vasomotor function, dyspareunia – menopause; atrophic vulva; carcinoma of prostate; decreased estrogen level; dysfunctional uterine bleeding; metastatic breast cancer | IV Powder for Soln: 25mg; Oral Tablet: 0.3, 0.45, 0.625, 0.9, 1.25mg; Vaginal Cream: 0.625mg/gm | IV, Oral, Vaginally | Varies | N/A (however, estrogen therapy has been used for induction of puberty) | Binds to nuclear receptors in estrogen-responsive tissues; modulates the pituitary secretion of the gonadotropins, LH, FSH, through a negative feedback mechanism, reducing the levels of these hormones seen in postmenopausal women |
Endocrine Metabolic Agent; Selective Estrogen Receptor Momdulator | Evista | Raloxifene | Breast Cancer, Osteoporosis | Oral Tablet: 60mg | Oral | 60mg QD | N/A | (SERM) selectively activates and blocks estrogenic paths by binding to specific estrogen receptors |
Nutriceutical; Nutritive Agent; Vitamin B | Folic Acid | Folic Acid | Megaloblastic Anemia,folic acid deficiency | Inj. Soln: 5mg/ml;cap:5mg,2000mcg Oral Tablet: 0.4mg, 0.8mg, 1mg, 800mcg | Oral, SubQ, IV, IM | Deficiency:0.4-0.8mg/day; homocystinemia:0.5-5mg/day; Pregnancy prophylaxis:0.4-1mg/day | Deficiency;megaloblastic anemia :infants 0.1mg/d;<4yo 0.3mg/d;>4yo 0.4mg/d | After conversion to tetrahydrofolic acid, it’s necessary for erythropoiesis, synthesis of purine and thymidylates, metabolism of amino acids (gly. and met. and the metabolism of histidine |
Antimuscarinic; Urinary Antispasmodic | Detrol; Detrol LA | Tolterodine | Overactive Bladder | Oral Tablet: 1, 2 mg; ER Capsule: 2, 4 mg | Oral | IR Tablet: Initial= 2mg BID, may lower dose to 1mg BID; ER Tablet: Initial= 4mg QD, may lower dose to 2mg QD | N/A | Competitive muscarinic receptor antagonist, mediating contraction of the urinary bladder and enhances salivation |
Antimuscarinic; Urinary Antispasmodic | Vesicare | Solifenacin | Overactive Bladder | Oral Tablet: 5, 10mg | Oral | 5-10mg QD | N/A | Exerts competitive antagonists effects at the muscarinic receptor |
Αlpha-1 Blocker; Benign Prostatic Hypertrophy Agent | Flomax | Tamsulosin | Benign prostatic hyperplasia | Oral Capsule: 0.4mg | Oral | Initial = 0.4mg QD, if no response after 2 to 4 weeks, may increase to 0.8mg QD Take 30min after same meal QD | N/A | Alpha-1 antagonist, selectively blocks sympathetic nervous stimulation of the receptor relaxation of the smooth muscles of prostate, prostatic urethra and bladder neck for improvement in urine flow rate |
Anti-hypertensive; Erectile Dysfunction Agent; PDE5 Inhibitor | Cialis | Tadalafil | Erectile Dysfunction Benign prostatic hyperplasia; Pulmonary HTN | Oral Tablet: 2.5, 5, 10, 20mg | Oral | Varies ED: 2.5mg QD or 10mg 30min prior to sexual activity BPH: 5mg QD | N/A | PDE5 inhibitor |
Anti-hypertensive; Erectile Dysfunction Agent; PDE5 Inhibitor; Vasodilator | Viagra | Sildenafil | Erectile dysfunction; Pulmonary HTN (Revatio only) | Oral Tablet: 25, 50, 100mg (Another brand name = Revatio, available in IV Soln. 10mg/12.5ml) | Oral | 25-100mg (50mg is usual dose) 1 hour prior to sexual activity; max of 1 dose per day | N/A | Inhibitor of cGMP specific PDE5 in smooth muscle where PDE5 is responsible for degradation of cGMP |
Bisphosphonate; Ca2+ Regulator | Actonel; Atelvia | Risedronate | Osteoporosis; Paget’s disease; postmenopausal osteoporosis | Oral Tablet: 5, 30, 35, 150mg; Delayed Release Tablet: (Atelvia) 35mg | Oral | Varies | N/A | Binds to bone hydroxyapatite, and at the cellular level, inhibits osteoclast activity, thereby modulating bone metabolism |
Bisphosphonate; Ca2+ Regulator | Boniva | Ibandronate | Postmenopausal osteoporosis | Oral Tablet: 150mg; IV Soln: 1mg/ml | Oral, IV | 2.5mg QD or 150mg once a month; IV: 3mg infused over 15-30 seconds every 3 months | N/A | Inhibits osteoclast-mediated bone resorption and turnover leading to a net gain in bone mass |
Bisphosphonate; Ca2+ Regulator | Fosamax | Alendronate | Osteoporosis; Paget’s disease; postmenopausal osteoporosis | Oral Soln: 70mg/75ml; Oral Tablet: 5, 10, 35, 40, 70mg; Effervescent Tab: 70mg | Oral | Typically 70mg once a week | N/A | Binds to bone hydroxyapatite and inhibits osteoclast-mediated bone resorption |
Androgen; Endocrine-Metabolic Agent | Androderm (Patch); AndroGel (Gel); Delatestryl (IM); Depo-Testosterone(IM); Striant (Buccal); Testim (Gel); Testopel (Implant) | Testosterone | Hypogonadism, Delayed Male Puberty | Transdermal Patch (ER): 2mg/24hr, 4mg/24hr, Topical gel/jelly: 1 or 1.62%; Buccal patch (ER): 30mg; SubQ Implant: 75mg; IM Susp: 100mg/ml 200mg/ml | Topically, Buccal, IM | Varies | N/A Adolescent males 13+ (IM and Pellet) | Endogenous androgen responsible for normal growth & development of male sex organs |
Adrenal Glucocorticoid; Anti-inflammatory; Corticosteroid; Dental Agent; Endocrine-Metabolic Agent | Aristocort; Kenalog; Nasacort | Triamcinolone Acetonide | Acquired Hemolytic Anemia; allergic rhinitis; asthma; collagen disease; disorder of endocrine system, eye, GI tract, respiratory system, skin; ganglion & synovial cyst; inflammatory disorder of musculoskeletal system; leukemia; malignant lymphoma; MS; | Inj. Susp: 10mg/ml, 40mg/ml; mucous membrane paste 0.1%; nasal spray: 55mcg/spray; topical cream & ointment; 0.025, 0.1, 0.5%; topical lotion: 0.025, 0.1%; topical spray: 0.147mg/gm | Intra-articular, intralesional, IM, intravitreal, nasal, topical | Varies | Varies 2YO+ nasal (dental paste – not for children) | Synthetic corticosteroid with anti-inflammatory, antipruritic and antiallergic properties |
Monophasic Contraceptive Combo (Estrogen and Progestin) | Aviane; Alesse; Loestrin 24 Fe; Ortho Novum; Ovcon; Ovral; Ortho-Cept; Sprintec; Yasmin; Yaz; | Monophasic Contraceptive Combo | Contraception | Varies | Oral | 1 tab QD, same time each day | Safety & efficacy before menarche have not been established | Suppresses gonadotropins; prevents ovulation and induces changes in the endometrium and cervical mucus to decrease the possibility of fertilization and implantation |
Monophasic Contraceptive Combo | Ortho Evra | Ethinyl Estradiol/ Norelgestromin | Contraception | Transdermal Patch (ER): 35mcg/24hr 150mcg/24hr | Transdermal | 1 patch every week for 3 weeks, patch-free for week 4 | Safety & efficacy before menarche have not been established | Suppresses gonadotropins; inhibits ovulation; changes cervical mucus and the endometrium |